Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases

被引:106
作者
Aiken, Alexander M. [1 ]
Hill, Philip C. [1 ]
Fox, Annette [1 ]
McAdam, Keith P. W. J. [1 ]
Jackson-Sillah, Dolly [1 ]
Lugos, Moses D. [1 ]
Donkor, Simon A. [1 ]
Adegbola, Richard A. [1 ]
Brookes, Roger H. [1 ]
机构
[1] MRC Labs, TB Div, Banjul, Gambia
基金
英国医学研究理事会;
关键词
D O I
10.1186/1471-2334-6-66
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: New tools are required to improve tuberculosis ( TB) diagnosis and treatment, including enhanced ability to compare new treatment strategies. The ELISPOT assay uses Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the immune response to pathogen. We hypothesized that TB patients in The Gambia would have reduced ELISPOT counts after successful treatment. Methods: We recruited Gambian adults with sputum smear and culture positive tuberculosis for ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart, comparing within and between subject variation. Results: We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive, 77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment: 44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a mean decline of 25, 44 and 47 SFU/2 x 10(5) cells for CFP-10, ESAT-6 and PPD respectively ( p < 0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all 4 not cured subjects ( 3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months. Conclusion: Successful tuberculosis treatment is accompanied by a significant reduction in the M. tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is warranted.
引用
收藏
页数:6
相关论文
共 18 条
[11]   Global epidemiology of tuberculosis [J].
Maher, D ;
Raviglione, M .
CLINICS IN CHEST MEDICINE, 2005, 26 (02) :167-+
[12]   Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: Implications for diagnosis and monitoring of therapy [J].
Nicol, MP ;
Pienaar, D ;
Wood, K ;
Eley, B ;
Wilkinson, RJ ;
Henderson, H ;
Smith, L ;
Samodien, S ;
Beatty, D .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :1301-1308
[13]   Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals:: Associations with clinical disease state and effect of treatment [J].
Pathan, AA ;
Wilkinson, KA ;
Klenerman, P ;
McShane, H ;
Davidson, RN ;
Pasvol, G ;
Hill, AVS ;
Lalvani, A .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :5217-5225
[14]   GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS - MORBIDITY AND MORTALITY OF A WORLDWIDE EPIDEMIC [J].
RAVIGLIONE, MC ;
SNIDER, DE ;
KOCHI, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (03) :220-226
[15]   Immune responses to mycobacterial antigens in the Gambian population: Implications for vaccines and immunodiagnostic test design [J].
Vekemans, J ;
Ota, MOC ;
Sillah, J ;
Fielding, K ;
Alderson, MR ;
Skeiky, YAW ;
Dalemans, W ;
McAdam, KPWJ ;
Lienhardt, C ;
Marchant, A .
INFECTION AND IMMUNITY, 2004, 72 (01) :381-388
[16]  
*WHO, WHO REP MON PROGR MI
[17]  
*WHO, 2005, WHOHTMTB2005349
[18]   Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis [J].
Wu-Hsieh, BA ;
Chen, CK ;
Chang, JH ;
Lai, SY ;
Wu, CHH ;
Cheng, WC ;
Andersen, P ;
Doherty, TM .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1336-1340